Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Liposomes
Reexamination Certificate
1998-10-08
2004-02-24
Kishore, Gollamudi S. (Department: 1615)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Liposomes
C424S649000, C514S492000
Reexamination Certificate
active
06696079
ABSTRACT:
BACKGROUND OF THE INVENTION
The present invention relates to methods and compositions for the treatment of cancer.
One drug that has proven effective in the treatment of certain tumors is cisplatin (cis-dichlorodiamine-platinum(II)). However, cisplatin has certain disadvantages. For example, its use in some circumstances is limited by its toxicity to the patient, especially its nephrotoxicity. As another example, tumors sometimes develop resistance to cisplatin.
In an effort to overcome the disadvantages of cisplatin, researchers have synthesized and tested various other platinum complexes as potential antitumor agents. One such compound is dichloro(1,2-diaminocyclohexane) platinum(II) (referred to in the remainder of this patent as “DACH—Pt—Cl
2
”). However, this compound has very low solubility in water, making it impractical for formulation and administration in aqueous solution. Further, although various platinum complexes have been formulated in liposomes in the past, a liposomal formulation of DACH—Pt—Cl
2
has not been developed because that complex is insoluble in most organic solvents. Although it has good solubility in dimethylformamide, that solvent has a very high boiling point, therefore making it impossible or impractical to prepare a liposomal formulation of DACH—Pt—Cl
2
using standard evaporation methods.
Other platinum-based antitumor drugs, such as cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum (II) (NDDP) have been prepared and tested as antitumor agents. However, a need still exists for improved antitumor drug formulations that have good antitumor activity, low toxicity to non-cancerous cells in a patient, and desirable storage characteristics.
SUMMARY OF THE INVENTION
The present invention relates to a liposomal antitumor composition and to methods of using the composition to inhibit tumor growth in mammals. The invention also concerns methods of preparing the antitumor composition.
The present invention can take advantage of intraliposomal conversion of a platinum complex having the formula
into a complex having the formula
R
1
—Pt—X
2
(II)
where X is halogen. This makes it possible to prepare liposomal formulations of the complex (II), which had not been practical previously due to its low solubility in water and most organic solvents.
In the above complexes, R
1
is diaminocycloalkyl, preferably a 1,2-diaminocycloalkyl group having from about 3 to about 6 carbon atoms, most preferably 1,2-diaminocyclohexane. R
2
and R
3
each have the formula
where R
4
, R
5
, and R6 are each independently hydrocarbon moieties having from 1 to about 10 carbon atoms, preferably alkyl having from 1 to about 6 carbon atoms, most preferably alkyl having from 1 to about 3 carbon atoms. R
2
and R
3
can be the same but do not have to be the same. Likewise, R
4
, R
5
, and R
6
can be the same but do not have to be the same. X is most preferably chlorine.
One aspect of the present invention is a liposomal antitumor composition that comprises the complex (II) entrapped in a liposome. In a particular embodiment of the invention, the liposome comprises an acidic phospholipid, for example dimyristoyl phosphatidyl glycerol. Without being bound by theory, it is believed that the presence of the acidic phospholipid in the liposome enhances or accelerates the conversion of the complex (I) to the complex (II).
Another aspect of the present invention is a method of inhibiting tumor growth. The method comprises administering to a mammal a composition that comprises the complex (II) entrapped in a liposome, with the platinum complex being present in an amount effective to inhibit tumor growth.
Another aspect of the present invention is a method of preparing the antitumor composition. This method comprises the step of adjusting the pH of a composition that comprises the platinum complex (I) entrapped in a liposome, whereby the pH is made somewhat acidic, preferably between about 2 and about 6.5, resulting in the conversion of the complex (I) into the complex (II). The resulting composition can then be administered to a patient.
In one particular embodiment of this method, the complex (I) is converted to the complex (II) within the liposome. This allows a liposomal formulation of the complex (I) to be manufactured and stored, and then shortly before administration to a patient, the liposomal formulation of complex (I) can be converted to a liposomal formulation of complex (II) in situ by simply adding an acidic solution to the formulation. Optionally, after a predetermined time has passed since the addition of the acidic solution, the pH can be readjusted, preferably to at least about 7, in order to stop the conversion of complex (I) to (II).
A broader aspect of the invention concerns a method of delivering a biologically active chemical moiety internally to a mammal. The biologically active moiety can be, for example, an antitumor agent. The method comprises (a) providing an aqueous formulation of a prodrug of the biologically active moiety, the prodrug being entrapped in a liposome, and the prodrug further being capable of forming the biologically active moiety upon exposure to a solution having an acidic pH; (b) reducing the pH to an acidic level, thereby converting the prodrug to the biologically active compound; and (c) administering the aqueous formulation to a mammal. Administration of the liposomal formulation to the mammal can suitably be done after the conversion of the prodrug, but it might also be done before conversion, such that the conversion would then occur in vivo, for example due to acidic components (e.g., acidic phospholipids) of the liposome.
The present invention has a number of advantages over prior art platinum antitumor formulations and methods, including better antitumor activity, greater potency, and reduced toxicity to non-cancerous cells of the patient. Further, the compositions of the present invention permit the formulation in liposomes and the delivery of platinum complexes that could not be so formulated in the past.
REFERENCES:
patent: 3904663 (1975-09-01), Tobe et al.
patent: 4169846 (1979-10-01), Kidani
patent: 4200583 (1980-04-01), Kidani et al.
patent: 4203912 (1980-05-01), Hydes et al.
patent: 4230631 (1980-10-01), Hydes et al.
patent: 4255347 (1981-03-01), Kidani et al.
patent: 4256652 (1981-03-01), Kidani et al.
patent: 4431666 (1984-02-01), Bulten et al.
patent: 4466924 (1984-08-01), Verbeek et al.
patent: 4661516 (1987-04-01), Brown et al.
patent: 4758588 (1988-07-01), Brown et al.
patent: 4760155 (1988-07-01), Heffernan et al.
patent: 4760157 (1988-07-01), Child et al.
patent: 4845124 (1989-07-01), Kidani et al.
patent: 4861905 (1989-08-01), Nowatari et al.
patent: 4946954 (1990-08-01), Talebian et al.
patent: 4956459 (1990-09-01), Talebian et al.
patent: 5011959 (1991-04-01), Khokhar et al.
patent: 5041578 (1991-08-01), Khokhar
patent: 5041581 (1991-08-01), Khokhar et al.
patent: 5117022 (1992-05-01), Khokhar
patent: 5178876 (1993-01-01), Khokhar
patent: 5186940 (1993-02-01), Khokhar et al.
patent: 5384127 (1995-01-01), Perez-Soler
patent: 5422364 (1995-06-01), Nicolau
patent: 0113508 (1984-07-01), None
patent: 0130482 (1985-01-01), None
patent: 0136012 (1985-04-01), None
patent: 0147926 (1985-07-01), None
patent: 0193936 (1986-09-01), None
patent: 0237450 (1987-09-01), None
patent: 0 193 936 (1989-05-01), None
patent: 0356332 (1990-02-01), None
patent: 87/02364 (1987-04-01), None
patent: 88/03925 (1988-06-01), None
patent: 90/02131 (1990-03-01), None
Sun Oncology. 40 372-376, 1983.*
Yatriw M Proc. Am. Assoc. Can Res 21 281 (Abstract, 1980.*
Han et al., 1996, “Intraliposomal conversion of lipophiliccis-bis-carboxylato-trans-R,R-1,2-diaminocyclohexane-platinum (II) complexes intocis-bis-dichloro-trans-R,R-1,2-diaminocyclohexane-platinum (II)”, Cancer Chemother. Pharmacol. 39:17-24.
Han et al., Cellular pharmacology of liposomal cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexaneplatinum(II) in A2780/S and A2780/PDD cells. Cancer Res. 53:4913-19, 1993.
Han et al., Intraliposomal conversion of lipophilic 1,2-D
Khokhar Abdul R.
Perez-Soler Roman
Board of Regents , The University of Texas System
Kishore Gollamudi S.
Pennie & Edmonds LLP
LandOfFree
Delivery and activation through liposome incorporation of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Delivery and activation through liposome incorporation of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Delivery and activation through liposome incorporation of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3349008